Posted: October 2, 2013 at 11:40 am
Healing With Stem Cell Therapy
http://www.ihealthtube.com http://www.facebook.com/ihealthtube Stem cell treatments have long been controversial, mostly because they started with the use of...
By: iHealthTube.com
See the rest here:
Healing With Stem Cell Therapy - Video
Posted: October 1, 2013 at 2:46 pm
MIAMI (PRWEB) October 01, 2013
The Global Stem Cells Group, Inc. has announced a worldwide alliance with Fort Myers, Florida-based EmCyte Corporation to promote in- office regenerative medicine procedures for physicians and practitioners.
EmCyte, a leading provider of biotechnology solutions in the United States, develops biological products for platelet rich plasma and bone marrow concentrate grafting procedures. The company also manufactures proprietary devices designed for harvesting the patients own plasma or bone marrow to use for the patients treatment.
EmCyte provides clinical support and trains physicians in using biologics for sports and general rehabilitative procedures. EmCyte is now seeking to expand its operations trough the Global Stem Cells Group Network.
The Global Stem Cells Groups collaboration with EmCyte is a logical one, as both companies are committed to research and development of products and procedures that will bring stem cell treatments to patients right in the physicians office.
Through its six separate stem cell companies, Global Stem Cell Group is dedicated to finding opportunities like the EmCyte alliance that help expand the reach of stem cell therapy to all patients who can benefit from it.
For more information on stem cell research, products and therapies, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
Continued here:
Global Stem Cells Group, Inc. Announces Worldwide Alliance with EmCyte Corp. to Promote In-office Regenerative ...
Posted: October 1, 2013 at 2:46 pm
Sep. 30, 2013 Mayo Clinic researchers are part of the second phase of a national consortium that focuses on developing innovative medical treatments for wounded veterans. Mayos role will emphasize peripheral nerve regeneration. Mayos principal investigator is Anthony Windebank, M.D., a neurologist and deputy director for discovery in the Mayo Clinic Center for Regenerative Medicine. Other organizations will focus on head and face trauma, burns, transplants and other conditions.
The opportunity to work together with a multidisciplinary, multi-institutional team that will create new therapies for our injured service members is a privilege, and we are proud that Mayo Clinic will be able to make a contribution to this effort, says Dr. Windebank. Other Mayo investigators include Michael Yaszemski, M.D., Ph.D., biomedical engineering and orthopedics; Allen Bishop, M.D., orthopedics; Alexander Shin, M.D., orthopedics; and Robert Spinner, M.D., neurologic surgery.
The consortium -- the Armed Forces Institute of Regenerative Medicine (AFIRM) -- is part of a national effort created to address the health care challenges of severely injured veterans returning from Afghanistan and Iraq. It is funded by the Army Medical Research and Materiel Command, in conjunction with the Office of Naval Research and the National Institutes of Health.
The first phase of AFIRM, which began in 2008, resulted in clinical studies of face transplantation, minimally invasive surgery for craniofacial injuries, a lower-dose anti-rejection regimen after kidney transplantation, scar reduction treatments, fat grafting for reconstructive surgery and new treatments for burns. The second phase (AFIRM-II) is a five-year, $75 million project and will focus on developing clinical therapies.
AFIRM-II will build on the efforts of the first five years, using regenerative medicine to develop new products and therapies to repair battlefield injuries. Regenerative medicine employs cell therapy (including stem cells), tissue and biomaterials engineering, and transplants to enable the body to repair, replace, restore and regenerate damaged tissues and organs. It will accelerate the rate at which biomaterials and technologies are converted into therapies to restore lost tissue and function. These products and therapies also will serve civilian trauma and burn patients.
The Mayo Clinic Center for Regenerative Medicine is honored to partner in this national effort poised to transform the care of severely wounded veterans. Advances in regenerative technologies promise unprecedented benefits for patients, their families and society, says Andre Terzic, M.D., Ph.D., the Michael S. and Mary Sue Shannon Family Director, Center for Regenerative Medicine, and Marriott Family Professor of Cardiovascular Diseases Research at Mayo Clinic.
See more here:
Researchers apply regenerative medicine to battlefield injuries
Posted: October 1, 2013 at 1:41 pm
CESMA: Deploying Stem Cells 20, T Gen Federico MARMO Conclusioni
T Gen Federico Marmo Ispettore Generale Sanità Militare.
By: aosbrief
Visit link:
CESMA: Deploying Stem Cells 20, T Gen Federico MARMO Conclusioni - Video
Posted: October 1, 2013 at 1:44 am
Public release date: 30-Sep-2013 [ | E-mail | Share ]
Contact: Jennifer Schutz newsbureau@mayo.edu 507-284-5005 Mayo Clinic
ROCHESTER, Minn. -- Mayo Clinic researchers are part of the second phase of a national consortium that focuses on developing innovative medical treatments for wounded veterans. Mayo's role will emphasize peripheral nerve regeneration. Mayo's principal investigator is Anthony Windebank, M.D., a neurologist and deputy director for discovery in the Mayo Clinic Center for Regenerative Medicine. Other organizations will focus on head and face trauma, burns, transplants and other conditions.
"The opportunity to work together with a multidisciplinary, multi-institutional team that will create new therapies for our injured service members is a privilege, and we are proud that Mayo Clinic will be able to make a contribution to this effort," says Dr. Windebank. Other Mayo investigators include Michael Yaszemski, M.D., Ph.D., biomedical engineering and orthopedics; Allen Bishop, M.D., orthopedics; Alexander Shin, M.D., orthopedics; and Robert Spinner, M.D., neurologic surgery.
The consortium -- the Armed Forces Institute of Regenerative Medicine (AFIRM) -- is part of a national effort created to address the health care challenges of severely injured veterans returning from Afghanistan and Iraq. It is funded by the Army Medical Research and Materiel Command, in conjunction with the Office of Naval Research and the National Institutes of Health.
The first phase of AFIRM, which began in 2008, resulted in clinical studies of face transplantation, minimally invasive surgery for craniofacial injuries, a lower-dose anti-rejection regimen after kidney transplantation, scar reduction treatments, fat grafting for reconstructive surgery and new treatments for burns. The second phase (AFIRM-II) is a five-year, $75 million project and will focus on developing clinical therapies.
AFIRM-II will build on the efforts of the first five years, using regenerative medicine to develop new products and therapies to repair battlefield injuries. Regenerative medicine employs cell therapy (including stem cells), tissue and biomaterials engineering, and transplants to enable the body to repair, replace, restore and regenerate damaged tissues and organs. It will accelerate the rate at which biomaterials and technologies are converted into therapies to restore lost tissue and function. These products and therapies also will serve civilian trauma and burn patients.
"The Mayo Clinic Center for Regenerative Medicine is honored to partner in this national effort poised to transform the care of severely wounded veterans. Advances in regenerative technologies promise unprecedented benefits for patients, their families and society," says Andre Terzic, M.D., Ph.D., the Michael S. and Mary Sue Shannon Family Director, Center for Regenerative Medicine, and Marriott Family Professor of Cardiovascular Diseases Research at Mayo Clinic.
The core academic partners of AFIRM-II are Mayo Clinic; Brigham and Women's Hospital; Case Western Reserve University; Cleveland Clinic; Georgia Institute of Technology; Jewish Hospital; Johns Hopkins University; Livionex Inc.; Massachusetts General Hospital; New York University School of Medicine; Northwestern University; Oregon Health & Science University; Radboud University Medical Center; Research Foundation of SUNY; Rice University; Stanford University School of Medicine; Rutgers, The State University of New Jersey; Southwest Research Institute, Stratatech Corporation; The Ohio State University College of Medicine; Tufts University; University of California, Los Angeles; University of Cincinnati, University of Connecticut; University of Florida; University of Louisville School of Medicine; University of Maryland School of Medicine, University of Michigan; University of Pittsburgh; UW Medicine; Vanderbilt University Medical Center; and Wake Forest University School of Medicine (Wake Forest Baptist Medical Center). These core partners are supported by a large number of industrial collaborators and participating health care companies that have expressed an interest in the commercialization of new products and therapies emerging from AFIRM's research program.
###
Here is the original post:
Mayo Clinic researchers apply regenerative medicine to battlefield injuries
Posted: October 1, 2013 at 1:42 am
Orange, CA (PRWEB) September 30, 2013
TeleHealth, the leading stem cell therapy clinic on the West Coast, is now offering multiple treatments with stem cells for knee arthritis. The stem cell treatments are very exciting as they present the possibility of repairing and regenerating arthritis damage in the knees. The treatments are offered by Board Certified stem cell doctors at the clinic in outpatient, low risk procedures that are often covered by insurance. Call (888) 828-4575 for more information and scheduling.
Over the past few years, increasing studies are showing the benefits of regenerative medicine treatments for knee arthritis. This includes a study out of the Hospital for Special Surgery last year showing effectiveness of platelet rich plasma therapy for knee arthritis. Treatment options at TeleHealth include both platelet rich plasma therapy (PRP therapy) along with bone marrow derived stem cell injection therapy or fat derived stem cell therapy.
Often, the treatments are combined to produce maximum knee arthritis benefit and allow patients to avoid surgery, reduce pain and dramatically increase functional ability. While knee replacement surgery has been shown to have a high success rate, the components are not meant to last forever and there can be complications with the surgery.
Therefore, it makes sense to try conservative treatment prior such as with the regenerative medicine options at TeleHealth. Especially considering the stem cell treatments are often covered by insurance.
TeleHealths main stem cell clinic is located in Orange, CA, convenient to major freeways and not far from San Diego, Los Angeles, Santa Ana and Inland Empire. The highly skilled stem cell doctors at the clinic are Board Certified and have years of experience treating musculoskeletal conditions with stem cell treatments including shoulder arthritis, rotator cuff tendonitis, Achilles tendonitis, tennis elbow, muscle tears and much more.
Call (888) 828-4575 for more information and scheduling.
Read this article:
Southern California Stem Cell Therapy Clinic, TeleHealth, Now Offering Stem Cells for Knee Arthritis
Posted: September 30, 2013 at 8:40 pm
130914 15 CESMA Deploying Stem Cells Terapie avanzate aspetti etici, Don Pablo REQUENA
By: aosbrief
Visit link:
130914 15 CESMA Deploying Stem Cells Terapie avanzate aspetti etici, Don Pablo REQUENA - Video
Posted: September 30, 2013 at 8:40 pm
government funding of stem cell research
Federal Grants, State Grants, Foundation Grants More! http://urlbit.es/govgrants Did you know that.... -- 15, 000, 000 individuals acquire free of charge a...
By: Amy knowing
See the original post:
government funding of stem cell research - Video
Posted: September 30, 2013 at 3:42 am
CESMA: Deploying Stem Cells 13, Prof Augusto Pessina: Introduzione panel ASPETTI NORMATIVI ED ETICI
Prof. Augusto PESSINA - Associato di Microbiologia e Microbiologia Clinica, Coordinatore Gruppo Italiano Staminali Mesenchimali (GISM) introduzione al panel ...
By: aosbrief
See the original post:
CESMA: Deploying Stem Cells 13, Prof Augusto Pessina: Introduzione panel ASPETTI NORMATIVI ED ETICI - Video
Posted: September 30, 2013 at 3:42 am
Jose Guzman began gasping for breath while using his treadmill on the lowest setting and knew something was wrong. His search for answers led him to the diagnosis of a rare lung disease with no cure.
Guzman, 72, who arrived from Cuba penniless and built a thriving Miami travel agency, doesnt give up easily. He has signed on to be one of the first patients to participate in a clinical trial being launched at the University of Miami. Dr. Marilyn Glassberg has obtained approval from the Food and Drug Administration to launch the first U.S. clinical trial that will test whether mesenchymal stem cells given intravenously could be a therapy for patients with Guzmans rare lung disease, known as idiopathic pulmonary fibrosis. The disease strikes mostly men who are 55 and older and ex-smokers.
Glassberg, a pulmonologist and professor of medicine and surgery and director of the pulmonary division at the Interdisciplinary Stem Cell Institute at UMs Miller School of Medicine, has studied rare lung diseases for 20 years. She says this is her first real hope of extending or improving the lives of her patients who have this progressive and fatal lung disease, which often leads to death within five years of diagnosis.
Glassberg says it if successful, stem cells could be applied as a potential therapy for other, more common lung diseases such as asthma or emphysema.
We believe moving cell-based therapies to diseases like these make sense, Glassberg says.
For the clinical trial, Glassberg says she chose to first focus on a lung disease with the worst prognosis.
Once fibrosis is present, it is the end stage because the damaged cells dont know how to repair themselves, she explains. Our hope is that the stems cells will curb the acceleration.
The trials results could change the way doctors manage lung disease for patients and get them away from drugs that have not been effective, she said.
The idea for using intravenous mesenchymal stem cells as a treatment for lung disease came from the work of several researchers, including a UM colleague who had used stem cell therapies on cardiac patients, Glassberg says. While reading a report on Dr. Joshua Hares 2009 study that used stem cells to repair heart damage, Glassberg said she was struck by one of its findings: the cells infused into the heart noticeably improved lung function, too.
The probability made sense to Glassberg because the lungs are the first stop for injected stem cells, regardless of where they are targeted. She became convinced she should try to apply this therapy to the pulmonary disease that has frustrated her for more than a decade.
Read more here:
Trial to determine if stem cells can help with rare lung disease
